Blog

Tirzepatide is a new class of medications being studied for the treatment of obesity. A once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor activator, Tirzepatide is a single peptide that triggers the body's receptors for GIP and GLP-1, two natural incretin hormones.

The most recent FDA approved weight loss medication, Semaglutide (also a GLP-1 activator) has been on the market for a while and has been a very successful option for weight loss. Countless patients here at Transformyou have had amazing results with Semaglutide. The new kid on the block looks to be Tirzepatide. Here are the details.

Obesity is a condition that affects over 40% of adults in the United States. Unfortunately, there is no magic pill that will cure it. There is, however, a new type of medicine that might be considered a game-changer. It’s an anti-obesity medication, and what makes it unique is how it’s prescribed: It is used to treat obesity as a chronic metabolic disease rather than assuming the misconception that obesity is a problem that can be overcome by willpower. In this article, we’ll take a look at what semaglutide is, how it works to support weight loss, other potential use cases, and the most common side effects to be aware of.

Although normally related to men, testosterone is one of the many hormones that women have within their bodies, affecting them throughout their lives. “Normal” levels of testosterone vary from one woman to another, but experts suggest that the range of healthy testosterone levels is between 15 ng/dL – 85 ng/dL.

In this article, find out more about low, normal, and high testosterone levels, as well as a brief explanation of their effects on the female body.

You've been eating healthier and exercising consistently. You're eating your fresh fruits and vegetables, complex carbs, lean meats, and you feel you're doing everything right to make your scale show the difference… but you're not seeing the weight loss numbers you had hoped for.